Oral therapy NUZ-001 cleared by FDA to join platform trial for ALS NUZ-001, an investigational oral therapy being developed by Neurizon Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS), is officially the ninth compound to be included in the HEALEY ALS platform trial
Neurizon Therapeutics After years of research and development, we are pioneering novel applications for NUZ-001 (S-Monepantel) Our initial focus is on Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease (MND)
NUZ-001 arm in HEALEY ALS trial expands to 240 participants The NUZ-001 arm of the HEALEY ALS trial is expanding enrollment to 240 participants NUZ-001 is an experimental ALS therapy designed to target the mTOR pathway and reduce toxic protein buildup Neurizon says the expansion may strengthen data analyses and support earlier top-line results
HEALEY ALS Platform Trial - Regimen I NUZ-001 Once Regimen I eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active NUZ-001 or matching placebo
Sean M. Healey AMG Center for ALS Announces First Participant . . . The trial will evaluate NUZ-001, an oral therapy that targets key pathological mechanisms in ALS, including TDP-43 protein aggregation and impaired autophagy, which are central features across multiple neurodegenerative diseases